Dr Richard Moreau and colleagues from France assessed which colloid, either albumin or synthetic colloids, can be used for plasma expansion.
Following paracentesis or other complications requiring fluid loading in patients with cirrhosis remains controversial.
The research team compared outcome and hospital-related cost in 68 patients with cirrhosis.
The team included 63 patients with ascites removal by paracentesis and 5 patients with ascites removal by paracentesis and renal impairment.
The primary end point was occurrence of a first liver-related complication.
The researchers team reported that the trial was prematurely discontinued because of safety concerns.
Of the included patients, 30 were assigned to receive albumin and 38 were assigned to receive a synthetic colloid.
|Liver complications adjusted to a 100-day period was lower in the albumin vs colloid group|
The patients were treated with either 20% human albumin or with a synthetic colloid of 4% polygeline.
The researchers found that the median time to first liver-related complication was not significantly longer in the albumin group.
However, the total number of liver-related complications adjusted to a 100-day period was significantly lower in the albumin group.
The team noted that median hospital cost for a 30-day period was significantly lower in the albumin group.
Dr Moreau's team commented, “In patients with cirrhosis and ascites, human albumin appears to be more effective in preventing liver-related complications than synthetic colloid.”
“This may be associated with decreased hospital costs.”